A 12-week treatment for eosinophilic esophagitis (EoE) in patients 11 years of age and older. EOHILIA has not been shown to be safe and effective for longer than 12 weeks.1

Patient Profiles for EOHILIA™ (budesonide oral suspension)

PATIENT PROFILES

EOHILIA is an oral option appropriate for a broad range of patients 11 years and older with variability in medical history.1,2

Identifying EOHILIA patient types

All patients are hypothetical.

Full image of Mike. (Not an actual patient.)

Not an actual patient.

Discontinued his swallowed aerosol steroid

Meet Mike, 35

“I struggled with swallowing something that is meant to be inhaled and would like to explore another oral option—one that’s made specifically for EoE.”

Diagnosed: 4 years ago

Comorbidities: Asthma, allergic rhinitis (controlled)

Previous therapy: Stopped taking swallowed steroid aerosols 4 weeks ago, used to take PPIs, and has used diet modification (restricted eggs, wheat, milk products)

Current presentation: Still seeking relief from his EoE symptoms

Clinical history
  • EoE diagnosis confirmed 4 years ago by a gastroenterologist based on
    • Symptom complaints: Dysphagia several times a week
    • Histological findings: Peak eosinophil count 65 eos/hpf
    • Endoscopic findings: Proximal rings and furrows with presence of exudates

Notes from patient
  • Reports excessive chewing, avoiding meals out with friends, and needing to drink water to relieve dysphagia symptoms several times in the last month
  • Comfortable with oral therapies and wants to try an oral option specifically intended for EoE
Full image of Kiana. (Not an actual patient.)

Not an actual patient.

Failed to control EoE symptoms with diet modification

Meet Kiana, 11

“Our daughter is starting to avoid eating at all. We are sensitive to her age and want a treatment that she could eventually learn to manage on her own as she becomes more independent.”

Diagnosed: 2 years ago

Comorbidities: Peanut allergy

Previous therapy: Diet modification (restricted seafood, wheat) most recently 3 months ago

Current presentation: Struggling with diet modification therapy and still experiencing EoE symptoms daily

Clinical history 
  • Suspected EoE after her mother noticed she was avoiding solid foods
  • Diagnosis was confirmed by a pediatric gastroenterologist 2 years ago based on
    • Symptom complaints (unsure of when they started): Choking and gagging with certain foods once a day; dysphagia once a day
    • Histological findings: Peak eosinophil count 47 eos/hpf
    • Endoscopic findings: Proximal stricture as well as edema and exudates in distal esophagus

Notes from patient
  • Her parents report that Kiana eats very little; she cuts food into small pieces, chews excessively, and drinks water with most bites of food
  • Kiana and her family would prefer a premixed oral option, one she can take with her on the go
Full image of Jackie. (Not an actual patient.)

Not an actual patient.

Previous slurry user

Meet Jackie, 41

“I can’t find a treatment that fits in my daily routine. I’m a busy working parent, and every minute matters.”

Diagnosed: 2 years ago

Comorbidities: None

Previous therapy: Stopped steroid slurries and PPIs 1 month ago; has used diet modification (restricted peanuts, milk products, eggs)

Current presentation: She felt that mixing steroid slurries was time-consuming, making it difficult to comply with her treatment. She is seeking another treatment option

Clinical history
  • Diagnosed after experiencing food impaction requiring emergency medical attention
  • Diagnosis confirmed by her gastroenterologist based on
    • Symptom complaints (on and off for more than 3 years): Dysphagia at almost every meal and food impaction a few times a week
    • Histological findings: Peak eosinophil count 102 eos/hpf
    • Endoscopic findings: Proximal esophageal stricture as well as distal rings and furrows
  • 2 prior esophageal dilations

Notes from patient
  • Complains about time it takes to make slurries and reports that, consequently, she’d miss doses
Full image of Luke. (Not an actual patient.)

Not an actual patient.

Steroid-naïve patient with EoE

Meet Luke, 25

“Now that I finally understand my condition, I want to know what options I have for treatment. I hope to find a treatment specifically for my EoE that fits into my busy life.”

Diagnosed: 8 months ago

Comorbidities: None

Previous therapy: Has been on a stable dose of PPIs for the past month; has used diet modification (restricted wheat and meat)

Current presentation: Despite a recent trial of PPI therapy, reports persistent EoE symptoms

Clinical history
  • His primary care physician (PCP) referred him to an allergist, who then referred him to a gastroenterologist for evaluation of dysphagia symptoms that increase when eating
  • Diagnosis was confirmed based on
    • Symptom complaints (less than a year): Vomiting to relieve dysphagia symptoms a few times a week
    • Histological findings: Peak eosinophil count 72 eos/hpf
    • Endoscopic findings: Exudates in the proximal esophagus, distal rings, and edema

Notes from patient
  • Avoids hard or lumpy foods and large meals
  • For his busy lifestyle, he wants to find an oral treatment option that does not need to be refrigerated

~1 in 2,000 

people in the U.S. are diagnosed with EoE

—and the prevalence has increased3-6

eos/hpf=eosinophils per high-power field; PPI=proton pump inhibitor.

PATIENT PROFILES

Save a copy of the patient profiles for your reference.

ORDER SAMPLES

You may have patients who could benefit from EOHILIA. Consider ordering a sample supply.

References:

  1. EOHILIA (budesonide oral suspension) Prescribing Information. Takeda Pharmaceuticals, Inc.
  2. Hirano I, Collins MH, Katzka DA, et al. Clin Gastroenterol Hepatol. 2022;20(3):525-534.e10.
  3. O’Shea KM, Aceves SS, Dellon ES, et al. Gastroenterology. 2018;154(2):333-345.
  4. Dellon ES, Hirano I. Gastroenterology. 2018;154(2):319-332.e3.
  5. Dellon ES. Gastroenterol Clin North Am. 2013;42(1):133-153.
  6. Dellon ES, Jensen ET, Martin CF, et al. Clin Gastroenterol Hepatol. 2014;12(4):589-596.e1.